31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this randomized clinical trial, rotigotine treatment did not significantly affect global cognition in patients with mild to moderate AD; however, improvement was observed in cognitive functions highly associated with the frontal lobe and in activities of daily living. 5 key findings →
Design: longitudinal study Participants: 47 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Early intervention to reduce caregiving behavioral burden and enhance family support and promote healthier behaviors of bereaved AD caregivers may decrease the risk of syndromal or syndromal-becoming-threshold level depression after loss. 3 key findings →
Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The GuidAge study is the largest study carried out in Europe on the prevention of AD. 2 key findings →
Design: randomized controlled trial Participants: 2,854 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Disclosure of pleiotropic information did not increase anxiety or depression and may have decreased distress among persons at increased risk for 2 conditions. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
After 3 months, IG improved gait speed (p = 0.016), implying a statistically significant difference between groups in favour of IG (p = 0.003). 3 key findings →
Design: randomized controlled trial Participants: 31 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There were no statistical differences between the placebo or solanezumab groups in CDR-G, CDR-SB, specific CDR boxes or CDR composite scores over the course of the trial. 3 key findings →
Participants: 583 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among 137 randomized participants, 2 were excluded for not meeting eligibility criteria, leaving 135 (mean [SD] age, 69.3 [3.8] years; 83 female [61%]) eligible for analysis. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In this Seminar, we highlight the main developments in the field of Alzheimer's disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
8 studies examined the association of sedentary behaviour with cognitive function. 6 studies reported significant negative associations between sedentary behaviour and cognitive function. 8 different measures of sedentary behaviour and 13 different measures of cognitive function were used across all eight studies. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Aerobic training significantly increased hippocampal volume in older women with probable MCI. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this population-based case-control study, any frequency of moderate exercise performed in midlife or late life was associated with a reduced odds of having MCI. 5 key findings →
Design: cohort study Participants: 1,324 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We found that severe COVID-19 infection, associated with a high mortality rate, might develop in a minority of fully vaccinated individuals with multiple co-morbidities. 5 key findings →
Design: cohort study Participants: 152 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Metformin should continue to be used as a first line therapy for diabetes in patients at risk of developing dementia or Alzheimer's disease. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Long-chain omega-3 fatty acids could have neuroprotective properties against dementia, which is becoming a major global public health issue. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Post-MI Hosp-CR and Home-CR are similarly effective in the short term and improve TWC and HRQL in each age group. 2 key findings →
Design: randomized controlled trial Participants: 90 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Physical exercise has been shown to increase brain volume and improve cognition in randomized trials of non-demented elderly. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The relationship between sensory impairment and cognitive impairment was not unique to one sensory system, suggesting that sensorineural health may be a marker of brain aging. 2 key findings →
Design: longitudinal study Participants: 1,884 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Observational studies support the use of NSAIDs for prevention of AD, but RCT do not. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
High intake of total, saturated, and trans fat and cholesterol and low intake of MUFA, PUFA, n-6 PUFA, and n-3 PUFA were not associated with increased risk of dementia or its subtypes. 4 key findings →
Design: cohort study Participants: 5,395 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Understanding how metabolites are longitudinally influenced by age and sex could facilitate the identification of metabolomic profiles and trajectories that indicate disease risk. 4 key findings →
Design: longitudinal study Participants: 1,212 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Controversies persist about the associations of body mass index (BMI) with risk of cognitive impairment and dementia. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Regular exercise, especially mind-body exercise with integrated cognitive and motor coordination, may help with preservation of global ability in elders at risk of cognitive decline; however, logistics to promote long-term practice and optimize adherence needs to be revisited. 3 key findings →
Design: randomized controlled trial Participants: 389 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This meta-analysis suggests that hearing impairment is associated with cognitive problems. 5 key findings →
Design: systematic review Participants: 602 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Dietary patterns and some dietary components have been linked with dementia. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events